JP2023156159A - がんリスクの試験方法 - Google Patents
がんリスクの試験方法 Download PDFInfo
- Publication number
- JP2023156159A JP2023156159A JP2022065853A JP2022065853A JP2023156159A JP 2023156159 A JP2023156159 A JP 2023156159A JP 2022065853 A JP2022065853 A JP 2022065853A JP 2022065853 A JP2022065853 A JP 2022065853A JP 2023156159 A JP2023156159 A JP 2023156159A
- Authority
- JP
- Japan
- Prior art keywords
- lat1
- cancer
- subject
- level
- specimen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 69
- 201000011510 cancer Diseases 0.000 title claims abstract description 66
- 238000010998 test method Methods 0.000 title claims abstract description 25
- 108091006232 SLC7A5 Proteins 0.000 claims abstract description 193
- 102000052922 Large Neutral Amino Acid-Transporter 1 Human genes 0.000 claims abstract description 68
- 238000012360 testing method Methods 0.000 claims abstract description 25
- 210000001124 body fluid Anatomy 0.000 claims abstract description 15
- 239000010839 body fluid Substances 0.000 claims abstract description 15
- 210000004369 blood Anatomy 0.000 claims abstract description 14
- 239000008280 blood Substances 0.000 claims abstract description 14
- 239000000439 tumor marker Substances 0.000 claims abstract description 13
- 210000002700 urine Anatomy 0.000 claims abstract description 6
- 238000011156 evaluation Methods 0.000 claims description 27
- 206010060862 Prostate cancer Diseases 0.000 claims description 21
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 21
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 239000013642 negative control Substances 0.000 claims 1
- 239000013641 positive control Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 32
- 238000010586 diagram Methods 0.000 abstract 1
- 102100038204 Large neutral amino acids transporter small subunit 1 Human genes 0.000 description 125
- 210000004027 cell Anatomy 0.000 description 64
- 239000000126 substance Substances 0.000 description 62
- 210000001808 exosome Anatomy 0.000 description 54
- 239000002609 medium Substances 0.000 description 18
- 238000011282 treatment Methods 0.000 description 18
- 238000001514 detection method Methods 0.000 description 17
- 238000001262 western blot Methods 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 239000003550 marker Substances 0.000 description 14
- 238000001794 hormone therapy Methods 0.000 description 13
- 102100037904 CD9 antigen Human genes 0.000 description 12
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 11
- 239000012099 Alexa Fluor family Substances 0.000 description 10
- 238000002372 labelling Methods 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 239000005556 hormone Substances 0.000 description 8
- 229940088597 hormone Drugs 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 108091023037 Aptamer Proteins 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 5
- 239000003098 androgen Substances 0.000 description 5
- 230000003100 immobilizing effect Effects 0.000 description 5
- 238000011528 liquid biopsy Methods 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 4
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 4
- 239000002771 cell marker Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 229960000997 bicalutamide Drugs 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000005199 ultracentrifugation Methods 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 229940123407 Androgen receptor antagonist Drugs 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 235000005956 Cosmos caudatus Nutrition 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 239000003936 androgen receptor antagonist Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000002795 fluorescence method Methods 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- VGIRNWJSIRVFRT-UHFFFAOYSA-N 2',7'-difluorofluorescein Chemical compound OC(=O)C1=CC=CC=C1C1=C2C=C(F)C(=O)C=C2OC2=CC(O)=C(F)C=C21 VGIRNWJSIRVFRT-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102000034263 Amino acid transporters Human genes 0.000 description 1
- 108050005273 Amino acid transporters Proteins 0.000 description 1
- 102100025222 CD63 antigen Human genes 0.000 description 1
- 102100027221 CD81 antigen Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 101000836492 Dictyostelium discoideum ALG-2 interacting protein X Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 1
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 1
- 101001134621 Homo sapiens Programmed cell death 6-interacting protein Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108700030796 Tsg101 Proteins 0.000 description 1
- 101150072717 Tsg101 gene Proteins 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 102000010660 flotillin Human genes 0.000 description 1
- 108060000864 flotillin Proteins 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 108091008104 nucleic acid aptamers Proteins 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 1
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022065853A JP2023156159A (ja) | 2022-04-12 | 2022-04-12 | がんリスクの試験方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022065853A JP2023156159A (ja) | 2022-04-12 | 2022-04-12 | がんリスクの試験方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023156159A true JP2023156159A (ja) | 2023-10-24 |
| JP2023156159A5 JP2023156159A5 (enExample) | 2025-04-17 |
Family
ID=88421236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022065853A Pending JP2023156159A (ja) | 2022-04-12 | 2022-04-12 | がんリスクの試験方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2023156159A (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7734807B1 (ja) * | 2024-08-09 | 2025-09-05 | 住友化学株式会社 | 判定方法、判定装置及びコンピュータプログラム |
-
2022
- 2022-04-12 JP JP2022065853A patent/JP2023156159A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7734807B1 (ja) * | 2024-08-09 | 2025-09-05 | 住友化学株式会社 | 判定方法、判定装置及びコンピュータプログラム |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6129305B2 (ja) | Ｃｌｅｃ１４ａに特異性を持つ新規な抗体及びその用途 | |
| JP7043548B2 (ja) | 乳癌検出のための試薬および方法 | |
| WO2014138183A1 (en) | Specific detection tool for mesenchymal and epithelial-mesenchymal transformed circulating tumor cells | |
| JP6386995B2 (ja) | 大腸がんの検出方法 | |
| EP2609429A2 (en) | Methods for detecting anti-he4 antibodies and methods of diagnosis and/or prognosis of conditions associated with he4-expressing cells | |
| KR20120078192A (ko) | 혈청 아밀로이드 ａ에 대한 단일클론항체 및 이를 생산하는 하이브리도마 세포 | |
| EP1424558A1 (en) | Reagent for assaying laminin 5 antigen in biological sample and assay method | |
| JP2023156159A (ja) | がんリスクの試験方法 | |
| CN103308689B (zh) | 用于预测雌性对象中患上癌症的风险或诊断癌症的方法 | |
| US20170097352A1 (en) | Immunoglobulin-bound extracellular vesicles and uses thereof | |
| JP5808288B2 (ja) | 微小胞膜タンパク質及びその応用 | |
| CN107110848A (zh) | 以脱氧羟腐胺缩赖氨酸合酶基因作为指标使用的动脉硬化及癌的检测方法 | |
| JP7006926B2 (ja) | 高安動脈炎の診断方法、診断マーカー及び診断キット | |
| CN112334487B (zh) | 用于诊断和治疗癌症的组合物和方法 | |
| US20240027474A1 (en) | Psp94 as blood biomarker for the non-invasive diagnosis of endometriosis | |
| JP6835332B2 (ja) | 動脈硬化を検出するための血中バイオマーカー | |
| JP7593669B2 (ja) | コンパニオン診断用バイオマーカー組成物およびこれを含むコンパニオン診断用キット | |
| WO2019050273A1 (ko) | 메티오닐 -티알엔에이 합성효소 및 선방세포 특이적 마커를 이용한 췌장암 진단 방법 | |
| CN111303289A (zh) | 抗人Tn型糖基化MUC1抗体及其用途 | |
| JP7565046B2 (ja) | がんの骨転移を検出する方法及び検出試薬 | |
| WO2025083329A1 (en) | Antibody binder as a biomarker for cancer | |
| WO2025025731A1 (zh) | 一种适用于免疫组化检测cd228的诊断抗体 | |
| JPWO2019009231A1 (ja) | 関節リウマチ診断薬 | |
| Li et al. | Immunochromatographic assay for rapid detection of SIGLEC15 to evaluate its therapeutic potential in cervical cancer | |
| JP2022083307A (ja) | 卵巣がんの診断を補助する方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A80 | Written request to apply exceptions to lack of novelty of invention |
Free format text: JAPANESE INTERMEDIATE CODE: A80 Effective date: 20220428 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20231107 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20231107 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250408 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250408 |